CD8A and liver disorder: Interestingly, our analysis of HCV therapy approaches and clinical factors on anti-HCV antibody dynamics revealed no significant correlations between anti-E2-Ab or anti-HCV-nAb titers and previous HCV therapy, type of treatment (IFN- or DAA-based), age, HCV viral load, CD4+ T-cell count, CD4/CD8 ratio, or liver disease stages.